Samara et al., 2014 - Google Patents
Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosisSamara et al., 2014
View PDF- Document ID
- 17622541736878353442
- Author
- Samara S
- Dailiana Z
- Chassanidis C
- Koromila T
- Papatheodorou L
- Malizos K
- Kollia P
- Publication year
- Publication venue
- Experimental and Molecular Pathology
External Links
Snippet
Introduction Femoral head avascular necrosis (AVN) is a recalcitrant disease of the hip that leads to joint destruction. Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor kappa-B (RANK) and RANK ligand (RANKL) regulate the balance between osteoclasts …
- 108010035042 Osteoprotegerin 0 title abstract description 103
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Samara et al. | Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis | |
| Farr et al. | Independent roles of estrogen deficiency and cellular senescence in the pathogenesis of osteoporosis: evidence in young adult mice and older humans | |
| Lories et al. | Pathophysiology of new bone formation and ankylosis in spondyloarthritis | |
| Wallner et al. | Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2 | |
| Grassi et al. | Hydrogen sulfide is a novel regulator of bone formation implicated in the bone loss induced by estrogen deficiency | |
| Buettmann et al. | VEGFA from early osteoblast lineage cells (Osterix+) is required in mice for fracture healing | |
| Liu et al. | HLA-B27–mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis | |
| Colditz et al. | Postnatal skeletal deletion of Dickkopf‐1 increases bone formation and bone volume in male and female mice, despite increased sclerostin expression | |
| Chan et al. | Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis | |
| Vanleene et al. | Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties | |
| Thiele et al. | Selective glucocorticoid receptor modulation maintains bone mineral density in mice | |
| Romero et al. | Pregnancy-associated genes contribute to antiluteolytic mechanisms in ovine corpus luteum | |
| Chung et al. | Roles of Wnt/β-catenin signalling pathway in the bony repair of injured growth plate cartilage in young rats | |
| Schminke et al. | A discoidin domain receptor 1 knock-out mouse as a novel model for osteoarthritis of the temporomandibular joint | |
| Krischek et al. | Network-based gene expression analysis of intracranial aneurysm tissue reveals role of antigen presenting cells | |
| Sakellariou et al. | Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters | |
| Abed et al. | R‐spondins are newly recognized players in osteoarthritis that regulate Wnt signaling in osteoblasts | |
| Wu et al. | Relative abundance of mature myostatin rather than total myostatin is negatively associated with bone mineral density in Chinese | |
| Kuek et al. | NPNT is expressed by osteoblasts and mediates angiogenesis via the activation of extracellular signal-regulated kinase | |
| Carrarelli et al. | Myostatin, follistatin and activin type II receptors are highly expressed in adenomyosis | |
| Morse et al. | Sclerostin antibody augments the anabolic bone formation response in a mouse model of mechanical tibial loading | |
| Czerny et al. | The association of IL-1β, IL-2, and IL-6 gene polymorphisms with bone mineral density and osteoporosis in postmenopausal women | |
| Shuai et al. | Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients | |
| Nalesso et al. | Calcium calmodulin kinase II activity is required for cartilage homeostasis in osteoarthritis | |
| Batoon et al. | Induction of osteoblast apoptosis stimulates macrophage efferocytosis and paradoxical bone formation |